



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

June 17, 2020

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816


Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited


M. Adinarayana
Company Secretary &
Vice President (Legal and Corp Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/6 /2020-2021

Press Release

Hyderabad, 17th June, 2020

NATCO records INR 2,022.4 Crore consolidated revenue and INR 458.1 Crore of profit, after tax, for the full year ended March 2020

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 2,022.4 Crore for the year ended on 31st March, 2020, as against INR 2224.7 Crore for the last year, reflecting a decline of around 9%, year-over-year. The net profit for the period, on a consolidated basis, was INR 458.1 Crore, as against INR 642.4 Crore last year, showing a decline of about 29%.

For the fourth quarter (Q4) ended March 31st, 2020, the company recorded a net revenue of INR 477.2 Crore, on a consolidated basis, as against INR 486.7 Crore during Q4, FY 2019. The profit after tax, on a consolidated basis, was recorded as INR 93.2 Crore for the quarter, as against INR 120.4 Crore same quarter last year.

The overall decline in revenue and profits, from prior year, was primarily due to continued decline in Hepatitis C product portfolio and to an extent in oncology segment due to pricing pressures. The company also faced slowdown in business operations during the fourth quarter due to supply chain issues amidst Covid-19 concerns, which were subsequently resolved.

Segmental Revenue Split (approx.), as below (All Figures in INR Crore)-

Segment	Revenue, Q4 FY20	Revenue, Full Year FY20
API	96.4	355.2
Formulations, Domestic	102.6	540.5
Formulations, Exports (incl. Profit Share)	200.9	824.9
Foreign Subsidiaries	18.5	108.5
Other Operating income	20.2	69.5
Other Income	38.6	123.8

The Board of Directors has recommended a fourth interim dividend of INR 1.00 per equity share of INR 2/- each, resulting in a total dividend payout of INR 6.75 per equity share for the year.

Forwarded for favour of publication
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)